Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan NV    MYL   NL0011031208

MYLAN NV (MYL)
Mes dernières consult.
Most popular
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/15/2017 08/16/2017 08/17/2017 08/18/2017 08/21/2017 Date
30.13(c) 30.47(c) 30.56(c) 30.72(c) 30.44(c) Last
6 564 933 8 994 741 8 867 793 7 185 271 5 724 002 Volume
+1.69% +1.13% +0.30% +0.52% -0.91% Change
More quotes
Financials ($)
Sales 2017 11 990 M
EBIT 2017 3 266 M
Net income 2017 1 422 M
Debt 2017 13 558 M
Yield 2017 -
Sales 2018 12 471 M
EBIT 2018 3 645 M
Net income 2018 2 080 M
Debt 2018 11 385 M
Yield 2018 -
P/E ratio 2017 13,08
P/E ratio 2018 9,43
EV / Sales2017 2,49x
EV / Sales2018 2,22x
Capitalization 16 324 M
More Financials
Company
Mylan N.V., is a pharmaceutical company which engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products.It operates through two segments: Generic and Specialty.The Generic pharmaceutical business is conducted... 
Sector
Pharmaceuticals
Calendar
11/02Earnings Release
More about the company
Surperformance© ratings of Mylan NV
Trading Rating : Investor Rating :
More Ratings
Latest news on MYLAN NV
08/17 MYLAN : Finalizes Settlement Agreement on Medicaid Rebate Classification for Epi..
08/14 MYLAN NV : Today's Research Reports on Stocks to Watch: Adamis Pharmaceuticals a..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/10 MYLAN : Advances Access in the Fight Against HIV with the Launch of Three Generi..
08/10 MYLAN NV : Featured Company News - Mylan Launches Avonza(TM) in India
08/10DJMylan Cuts View On Drug Delays -- WSJ
08/09DJMylan Defers Product Launches -- 3rd Update
08/09DJMylan Defers Product Launches -- 2nd Update
More news
Sector news : Pharmaceuticals - NEC
08:48aDJJOHNSON & JOHNSON : J&J to Appeal Verdict In Baby-Powder Case -- WSJ
08/21DJJOHNSON & JOHNSON : Hit With $417 Million Verdict in Baby Powder Case
08/21 FTSE teeters close to three-month low as financials fall
08/21 SHIRE : CFO resigns to join plant technology start-up
08/21DJSHIRE : Finance Head Jeff Poulton to Step Down
More sector news : Pharmaceuticals - NEC
Latest Tweets
08:01aMylan N.V. $MYL Stock Rating Reaffirmed by Mizuho  
08/21$MYL New SEC Document(s) for Mylan N.V. From our Stock News Alerts App 
08/21Co’s that have issued #guidance in the last 30 days  
08/21$SLDC MUST READ Free money?
1
08/20Mylan N.V. $MYL Downgraded to “Strong Sell” at BidaskClub  
More tweets
Qtime:123
News from SeekingAlpha
08/21 BIOTECH FORUM DAILY DIGEST : Agio Pharmaceuticals Back In The Spotlight
08/18 Mylan Inc 2017 Q2 - Results - Earnings Call Slides
08/18 SNIPPET ROUNDUP : Transparency For Straumann But A Black Box For Pfizer
08/18 Tracking John Paulson's Paulson & Company Portfolio - Q2 2017 Update
08/17 ANI Pharmaceuticals Valued Cheaply Ahead Of Re-Commercialization Of Corticotr..
Chart MYLAN NV
Duration : Period :
Mylan NV Technical Analysis Chart | MYL | NL0011031208 | 4-Traders
Technical analysis trends MYLAN NV
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 40,7 $
Spread / Average Target 34%
EPS Revisions
Managers
NameTitle
Heather M. Bresch Chief Executive Officer & Executive Director
Rajiv Malik President & Executive Director
Robert J. Coury Executive Chairman
Kenneth Scott Parks Chief Financial Officer
Wendy Cameron Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN NV-20.21%16 324
JOHNSON & JOHNSON15.83%355 979
NOVARTIS7.69%216 915
ROCHE HOLDING LTD.3.78%216 699
PFIZER0.86%194 554
MERCK AND COMPANY5.27%167 705